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ABSTRACT 
Randomized clinical trials are often designed to assess whether a test treatment prolongs survival 
relative to a control treatment. Increased patient heterogeneity, while desirable for generalizability 
of results, can weaken the ability of common statistical approaches to detect treatment differences, 
potentially hampering the regulatory approval of safe and efficacious therapies. A novel solution 
to this problem is proposed. A list of baseline covariates that have the potential to be prognostic 
for survival under either treatment is pre-specified in the analysis plan. At the analysis stage, using 
all observed survival times but blinded to patient-level treatment assignment, ‘noise’ covariates 
are removed with elastic net Cox regression.  The shortened covariate list is used by a conditional 
inference tree algorithm to segment the heterogeneous trial population into subpopulations of 
prognostically homogeneous patients (risk strata). After patient-level treatment unblinding, a 
treatment comparison is done within each formed risk stratum and stratum-level results are 
combined for overall statistical inference. The impressive power-boosting performance of our 
proposed 5-step stratified testing and amalgamation routine (5-STAR), relative to that of the 
logrank test and other common approaches that do not leverage inherently structured patient 
heterogeneity, is illustrated using a hypothetical and two real datasets along with simulation 
results. Furthermore, the importance of reporting stratum-level comparative treatment effects (time 
ratios from accelerated failure time model fits in conjunction with model averaging and, as needed, 
hazard ratios from Cox proportional hazard model fits) is highlighted as a potential enabler of 
personalized medicine. A fiveSTAR R package is available at   
https://github.com/rmarceauwest/fiveSTAR.  
 
KEYWORDS: conditional inference tree, elastic net regression, model averaging, risk stratum, 
stratified medicine, time ratio  
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1. INTRODUCTION 
Consider a typical randomized clinical trial designed to compare the effect of treatment A (test) 
versus treatment B (control) on a time-to-event endpoint, the latter hereafter generically referred 
to as survival time. We let the random variable 𝑇𝑇𝑗𝑗 denote survival time under treatment j so that 
𝑆𝑆𝑗𝑗(𝑡𝑡) = 𝑃𝑃𝑃𝑃�𝑇𝑇𝑗𝑗 > 𝑡𝑡� is the true proportion of patients in the overall target population with survival 
time greater than t for treatment j. The usual null hypothesis of interest is that the survival time 
distributions for the two treatments are the same, typically expressed as 
𝐻𝐻0: 𝑆𝑆𝐴𝐴(𝑡𝑡) = 𝑆𝑆𝐵𝐵(𝑡𝑡) for all t.           (1) 
With ℎ𝑗𝑗(𝑡𝑡) representing the true hazard function for treatment j, it is easy to see that 
∫ ℎ𝐴𝐴(𝑢𝑢)𝑑𝑑𝑢𝑢𝑡𝑡0 ∫ ℎ𝐵𝐵(𝑢𝑢)𝑑𝑑𝑢𝑢𝑡𝑡0 = −𝑙𝑙𝑙𝑙𝑙𝑙𝑆𝑆𝐴𝐴(𝑡𝑡)/−𝑙𝑙𝑙𝑙𝑙𝑙𝑆𝑆𝐵𝐵(𝑡𝑡) ≡ 𝜃𝜃(𝑡𝑡)� . If ℎ𝐴𝐴(𝑡𝑡) and ℎ𝐵𝐵(𝑡𝑡) are proportional 
to each other, 𝜃𝜃(𝑡𝑡) ≡ 𝜃𝜃 is the time-invariant hazard ratio and the null hypothesis can be written as 
𝐻𝐻0: 𝜃𝜃 = 1. The logrank test1-2 or, equivalently, the score test from the Cox proportional hazards 
(PH) model3 with only a treatment arm indicator, remains a popular option for testing H0 in 
randomized clinical trials.4-7 Two well-known issues emerge when the PH assumption is non-
trivially violated, as often seen8-13 in practice: the power of the logrank test can be substantially 
diminished and the hazard ratio estimate from the Cox PH model can be hard to interpret. 
 
One way to guard against a potential power loss associated with the logrank test under non-PH 
conditions is through the use of a weighted logrank test, commonly selected from the 𝐺𝐺𝜌𝜌,ϒ class of 
tests proposed by Harrington and Fleming14 with weight function 𝑤𝑤(𝑡𝑡) = {?̂?𝑆(𝑡𝑡)}𝜌𝜌{1 − ?̂?𝑆(𝑡𝑡)}𝛾𝛾 for 
𝜌𝜌, 𝛾𝛾 ≥ 0, where ?̂?𝑆(𝑡𝑡) is the Kaplan-Meier estimator of the pooled survival function at time t. Note 
that G0,0 ≡ Z1 is the logrank statistic which assigns equal weight to each event, while the statistics 
G1,0 ≡ Z2, G1,1 ≡ Z3 and G0,1 ≡ Z4 place more weight on early, middle and late events, respectively. 
If prior knowledge about the expected nature of the between-treatment difference in the overall 
survival functions is available at the trial design stage, then a prudent choice between these four Z 
statistics, or selection of an alternate 𝐺𝐺𝜌𝜌,ϒ statistic, can be made and pre-specified in the analysis 
plan. However, because such prior information is usually not available, versatile combinations of 
weighted logrank tests into single overall tests have been proposed by several authors,15-21 
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including the MaxCombo test21 which uses the minimum of Z1, Z2, Z3 and Z4 as the test statistic 
when a one-tailed hypothesis test is planned and negative Zi’s indicate directional support for the 
test versus the control treatment. 
 
Another way to mitigate the risk of reduced power associated with use of the logrank test under 
non-PH conditions, and to simultaneously avoid corresponding interpretational challenges with a 
single hazard ratio estimate, is to test 𝐻𝐻0 based on an integrated weighted average of an estimate 
of 𝑆𝑆𝐴𝐴(𝑡𝑡) − 𝑆𝑆𝐵𝐵(𝑡𝑡) over a time interval (0,τ].22 A version of this test based on equal weights at each 
time point, typically referred to as the restricted mean survival time (RMST) test, has been 
popularized within the past decade by several authors.23-26  Note that ψ(𝜏𝜏) = ∫ [𝑆𝑆𝐴𝐴(𝑡𝑡) − 𝑆𝑆𝐵𝐵(𝑡𝑡)]𝑑𝑑𝑡𝑡𝜏𝜏0  
is the true between-treatment difference in mean survival time restricted to the first τ time units of 
follow-up after treatment initiation. In practice, ψ(𝜏𝜏) is commonly estimated non-parametrically 
as the difference between the area under the Kaplan-Meier curve up to time τ for each treatment. 
An advantage of the RMST approach is that the proportional hazards assumption is not required 
to deliver a clinically interpretable quantification of the comparative treatment effect. However, 
whether and by how much the RMST test improves upon the power of the logrank test depends on 
the choice of τ, on the censoring patterns for the treatment arms being compared, and on the extent 
and nature of the departure from proportional hazards. 
 
Combinations of weighted logrank tests and the RMST test are indeed rational alternatives to the 
logrank test when a departure from PH is anticipated. However, all three approaches share the 
following two shortcomings.  First, they do not leverage a ubiquitous feature of randomized 
clinical trial populations, namely ‘structured’ patient heterogeneity (described below), and this can 
contribute to suboptimal power for testing 𝐻𝐻0. Second, even if the data support rejection of 𝐻𝐻0, 
none of the aforementioned approaches are designed to readily deliver quantitative metrics that aid 
in the assessment of whether the test treatment is likely to be survival-prolonging for all types of 
patients in the target population or only an identifiable subset. 
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The above observations motivate development of an alternate approach for survival analysis in 
randomized clinical trials. To head in that direction, with 𝑌𝑌𝑗𝑗 = 𝑙𝑙𝑙𝑙𝑙𝑙(𝑇𝑇𝑗𝑗), we begin by noting that 
∆ = 𝐸𝐸(𝑌𝑌𝐴𝐴 − 𝑌𝑌𝐵𝐵) is a statistically unambiguous causal estimand; it represents the expected within-
patient difference in log survival time between treatments A and B if each patient could 
hypothetically be observed under each treatment. In a parallel arm randomized clinical trial, only 
one of 𝑌𝑌𝐴𝐴 and 𝑌𝑌𝐵𝐵 can be observed for each patient, but ∆ can still be estimated with minimal bias 
under standard assumptions since 𝐸𝐸(𝑌𝑌𝐴𝐴 − 𝑌𝑌𝐵𝐵) = 𝐸𝐸(𝑌𝑌𝐴𝐴) − 𝐸𝐸(𝑌𝑌𝐵𝐵).   
 
Next, we envision the overall target patient population as being a finite mixture of distinct 
subpopulations, which we refer to as ‘risk strata’. Higher to lower ordered risk strata comprise of 
patients with clinical prognoses of shorter to longer expected survival regardless of assigned 
treatment. Patients within a given risk stratum are prognostically homogeneous in that they have 
in common certain pre-treatment characteristics that jointly strongly associate with survival time. 
In statistical parlance, the survival times under a given treatment for patients within a risk stratum 
are presumed to follow a common distribution. With random variable 𝑇𝑇𝑖𝑖𝑗𝑗 denoting the true survival 
time under treatment j for risk stratum 𝑖𝑖 (1 ≤ 𝑖𝑖 ≤ 𝑠𝑠) and 𝑌𝑌𝑖𝑖𝑗𝑗 = 𝑙𝑙𝑙𝑙𝑙𝑙(𝑇𝑇𝑖𝑖𝑗𝑗), we further envision that 
𝑌𝑌𝑖𝑖𝐴𝐴 is distributed as 𝑌𝑌𝑖𝑖𝐵𝐵 + ∆𝑖𝑖 so that ∆𝑖𝑖 = 𝐸𝐸(𝑌𝑌𝑖𝑖𝐴𝐴 − 𝑌𝑌𝑖𝑖𝐵𝐵) represents the expected within-patient 
difference in log survival time under treatments A and B within stratum i. This implies27 that 
𝑆𝑆𝑖𝑖𝐴𝐴(𝑡𝑡) = 𝑆𝑆𝑖𝑖𝐵𝐵(𝛾𝛾𝑖𝑖𝑡𝑡), where 𝑆𝑆𝑖𝑖𝑗𝑗(𝑡𝑡) = 𝑃𝑃𝑃𝑃�𝑇𝑇𝑖𝑖𝑗𝑗 > 𝑡𝑡� is the true proportion of patients in risk stratum i 
with survival time greater than t under treatment j and 𝛾𝛾𝑖𝑖 = 𝑒𝑒∆𝑖𝑖. We refer to 𝛾𝛾𝑖𝑖 as the true time 
ratio for patients in risk stratum i. It represents a comparative treatment effect with a 
straightforward clinical interpretation; for example, 𝛾𝛾𝑖𝑖 = 1.25 means that patients in risk stratum 
i are expected to have 25% longer survival under treatment A versus treatment B. 
 
The conceptualization described above implies that the causal estimand can now be expressed as 
∆ = ∑ 𝑓𝑓𝑖𝑖∆𝑖𝑖𝑠𝑠𝑖𝑖=1 , where 𝑓𝑓𝑖𝑖 is the proportion of patients in the entire target population that are in risk 
stratum i  (∑ 𝑓𝑓𝑖𝑖 = 1𝑠𝑠𝑖𝑖=1 ). The null hypothesis of interest is reformulated as 
          𝐻𝐻0∗:∆𝑖𝑖= 0 (i.e., 𝛾𝛾𝑖𝑖 = 1) for all i                   (2) 
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which is equivalent to 
    𝐻𝐻0∗:⋂ [𝑆𝑆𝑖𝑖𝐴𝐴(𝑡𝑡) = 𝑆𝑆𝑖𝑖𝐵𝐵(𝑡𝑡) ]𝑠𝑠𝑖𝑖=1  for all t.                   (3) 
Note that if 𝐻𝐻0∗ in (2) is true, then 𝐻𝐻0 in (1) is also true. Furthermore, if all the ∆𝑖𝑖’s have the same 
sign (an assumption that we do not require nor make), then 𝐻𝐻0∗ is equivalent to 
      𝐻𝐻0∗∗:∆ = 0 (i. e. , 𝛾𝛾 = 1) ,               (4) 
where 𝛾𝛾 = 𝑒𝑒∆ is the average (geometric mean) time ratio for the overall population.  
 
We propose the following approach to test the null hypothesis in (2) and to estimate the causal 
estimand ∆ (and subsequently 𝛾𝛾). A list of baseline covariates that have the potential to be 
prognostic for survival under either treatment is pre-specified in the analysis plan (Step 1). At the 
analysis stage, using all the observed survival times but blinded to patient-level treatment 
assignment, ‘noise’ covariates are removed with elastic net Cox regression (Step 2).  The shortened 
covariate list is subsequently used by a conditional inference tree algorithm to segment the 
heterogeneous trial population into subpopulations of prognostically homogeneous patients (risk 
strata) (Step 3). After patient-level treatment unblinding, a treatment comparison is done within 
each formed risk stratum (Step 4) and stratum-level results are combined for overall statistical 
inference (Step 5). 
 
Before proceeding further, it is important to differentiate the proposed strategy from the common 
use of the stratified logrank test for hypothesis testing and corresponding stratified Cox PH model 
for estimation based on pre-specified stratification factor(s). While this is generally a step in the 
right direction relative to the unstratified version of the logrank test and Cox PH model, we caution 
against this routine practice for two reasons. First, inclusion of a stratification factor that does not 
materially influence survival time under either treatment or exclusion of a stratification factor that 
does so can reduce power due to over-stratification or under-stratification, respectively, both due 
to model misspecification.28-29 Second, even with a proper choice of stratification factor(s), the 
stratified logrank test can suffer from a notable power loss either if the assumption of proportional 
hazards within each stratum is incorrect, or if the assumption is correct but the true hazard ratio is 
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not constant across the strata. The primary reason for the statistical inefficiency in the latter case 
is that the inverse-variance weighting scheme implicitly used to combine estimated stratum-level 
log hazard ratios for overall inference is suboptimal when there is a treatment by stratum 
interaction on the hazard ratio scale.30 In our proposal, instead of using pre-stratification and a 
corresponding stratified logrank/Cox PH model analysis, we use unbiased post-stratification in 
tandem with a new analysis approach that is intended to boost power for detecting a true between-
treatment difference in the distribution of survival times. Furthermore, for the primary analysis, 
we quantify comparative treatment effects using time ratios instead of hazard ratios, without any 
need for the proportional hazards assumption anywhere, and our null hypothesis and causal 
estimand of interest are clearly stated with a straightforward clinical interpretation. 
 
The rest of this article is structured as follows. In Section 2, we provide additional details for our 
proposed 5-step stratified testing and amalgamation routine (5-STAR). We subsequently contrast 
its performance with that of the unstratified logrank/Cox PH model, [pre-]stratified logrank/Cox 
PH model and RMST comparison strategies using a hypothetical and two real clinical trial datasets 
in Section 3 and simulations in Section 4. Concluding remarks are provided in Section 5. 
 
2. 5-STAR DETAILS  
The main concept behind our proposed 5-STAR approach is depicted schematically in Figure 1. 
Additional details for each step are given below. 
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Figure 1. 5-STAR schema  
 
Step 1: Pre-specify baseline covariates that may be prognostic for survival 
This step entails pre-specifying in the statistical analysis plan, ideally in collaboration with relevant 
subject matter experts, a list of baseline covariates that have the potential to influence survival 
times under either treatment. The proposed methodology can easily accommodate a reasonably 
large number of candidate covariates of differing types (continuous, ordinal, or nominal), so more 
inclusivity is recommended. However, this should be done within bounds of sound statistical, 
clinical and operational judgement, such as avoiding the nomination of candidate covariates that 
are unlikely to be used in routine clinical practice due to high cost, patient inconvenience or other 
reasons. We assume all prognostic covariates that define the true risk strata described in the 
Introduction, while unknown, are included in the candidate set.  
 
Step 2: Remove ‘noise’ covariates from the pre-specified candidate list 
In this step, while still blinded to patient-level treatment assignment, covariates without sufficient 
evidence of an association with observed survival times are removed from the candidate list 
developed in Step 1. We considered two ways to implement this covariate filtering step: (i) random 
survival forest with variable importance measures and associated bootstrap confidence intervals31-
32 and (ii) elastic net Cox regression.33-34 Since (i) and (ii) had similar performance during the 
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initial stages of this research (results not shown), we chose the latter due to computational 
simplicity. The objective function for elastic net Cox regression is 
 𝑚𝑚𝑚𝑚𝑚𝑚
𝛽𝛽1…𝛽𝛽𝑝𝑝 �2𝑁𝑁 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙�𝑡𝑡1 … 𝑡𝑡𝑁𝑁; 𝑚𝑚1 … 𝑚𝑚𝑝𝑝,𝛽𝛽1 …𝛽𝛽𝑝𝑝� − 𝜆𝜆 �𝜓𝜓∑ |𝛽𝛽𝑘𝑘|𝑝𝑝𝑘𝑘=1 + �1−𝜓𝜓2 �∑ 𝛽𝛽𝑘𝑘2𝑝𝑝𝑘𝑘=1 ��  ,            (5) 
where 𝑙𝑙(∙) is the Cox partial likelihood function based on the pooled potentially censored survival 
times (𝑡𝑡1 … 𝑡𝑡𝑁𝑁) and pre-specified baseline covariates (𝑚𝑚1 … 𝑚𝑚𝑝𝑝), 𝜆𝜆 ≥ 0 is a tuning parameter and 
𝜓𝜓 ∈ [0,1] is a mixing parameter. In (5), 𝜓𝜓 = 0 and 𝜓𝜓 = 1 yield objective functions for Cox 
regression with the well-known ridge35 and lasso36 penalties, respectively. The elastic net combines 
the strengths of the two approaches. 
 
To identify the optimal 𝜓𝜓 and 𝜆𝜆, we consider a grid of 𝜓𝜓 values {0.05, 0.1, 0.15, … , 0.95}. For each 
fixed 𝜓𝜓, we perform 10-fold cross-validation to determine the optimal value of 𝜆𝜆. Here, optimal 
can be defined either as the value of 𝜆𝜆 that directly minimizes the cross-validation deviance from 
the Cox partial likelihood model (denoted as 𝜆𝜆𝑚𝑚𝑖𝑖𝑚𝑚) or as the largest value of 𝜆𝜆 which yields cross- 
validation error that is within one standard error of the minimum deviance (denoted as 𝜆𝜆1𝑠𝑠𝑠𝑠); we 
use the former as a default for 5-STAR to reduce the risk of incorrectly eliminating prognostic 
covariates. Based on the optimized 𝜓𝜓 and 𝜆𝜆, all covariates with a non-zero coefficient in the final 
elastic net Cox regression model fit are advanced to Step 3.  
 
Step 3: Segregate the overall population into subpopulations (risk strata) of prognostically 
homogeneous patients 
After covariate filtering has been performed, still blinded to patient-level treatment assignment, 
the conditional inference tree (CTree) tool, an unbiased recursive partitioning algorithm developed 
by Hothorn et al,37 is used to segregate patients into well-separated risk strata. Briefly, for each 
covariate 𝑋𝑋𝑗𝑗, a permutation test is performed to assess the null hypothesis that the distribution of 
the pooled logrank scores conditional on 𝑋𝑋𝑗𝑗 is the same as the marginal distribution of the pooled 
logrank scores, resulting in p-value 𝑝𝑝𝑗𝑗. If at least one of the p-values is deemed statistically 
significant after a Sidak38 multiplicity adjustment, the algorithm splits the data based on the 
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covariate with the strongest association (i.e., with the smallest p-value). If the given covariate is 
binary, splitting into two nodes is straightforward. Otherwise, the split point is chosen to maximize 
the separation in the distribution of the logrank scores between the two forming nodes. The 
algorithm continues doing this separately under each formed node, switching between covariate 
selection and split determination. Newly formed nodes are grown in this manner until the null 
hypothesis of no association between the pooled logrank scores and any covariate in contention 
cannot be rejected or until predetermined criteria (e.g., requiring at least 40 patients per terminal 
node) are violated. Each terminal node represents a formed risk stratum. 
 
The CTree algorithm is a very useful patient segmentation tool. However, given the nature of the 
covariate-based sample splitting, it is possible to see diverging nodes from secondary splits which 
have similar survival profiles, visualized as approximately overlapping Kaplan-Meier curves. This 
can result in potential over-stratification. To avoid this, the 5-STAR method considers two 
iterations of the CTree algorithm, named Step 3A and Step 3B. In Step 3A, all covariates surviving 
the elastic net filtering step are input into the CTree algorithm to form preliminary patient risk 
strata, as described above. These preliminary nodes are then sorted from highest to lowest risk 
based on the area under the overall Kaplan-Meier curve from time zero until the minimax survival 
time (i.e., the minimum of the maximum observed survival times over all treatment-pooled strata) 
for patients within a given preliminary risk stratum. This results in an ordinal stratum variable, 
with value 1 for patients in the highest risk preliminary risk stratum, value 2 for patients in the 
second highest risk preliminary risk stratum 2, and so on. At the start of Step 3B, all patients are 
considered to be part of a single final risk stratum and permutation testing is performed to 
determine if there is sufficient statistical evidence of an association between the ordinal stratum 
variable and the pooled logrank scores. As in Step 3A, this second run of CTree iteratively grows 
a tree, finding the best split point across the ordinal stratum variable until meeting the stopping 
criteria. Of note, a split can separate, for example, ordered preliminary strata (1, 2) from (3, 4) but 
not (1, 3) from (2, 4). If all ordered preliminary strata are deemed by the algorithm to have 
statistically different survival profiles, the final formed strata are the same as the preliminary strata 
(i.e., all possible splits occur in Step 3B). Otherwise, those that are not deemed statistically 
different are pooled in an order restricted manner to form a smaller number of final strata. The 
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multiplicity-adjusted p-value thresholds for allowing nodal splits need to be pre-specified; we use 
𝛼𝛼3𝐴𝐴 = 0.10 and 𝛼𝛼3𝐵𝐵 = 0.20 as a default in Steps 3A and 3B, respectively. 
 
At the end of Step 3A and 3B, still blinded to patient-level treatment assignment, suppose a total 
of 𝑐𝑐 final risk strata are formed. A graph with overlaid Kaplan-Meier curves for each of the c 
formed risk strata can be helpful in judging the effectiveness of this critical risk-based patient 
segmentation step of 5-STAR; we show this with the three examples in the next Section. 
 
Step 4: Treatment comparison within each formed risk stratum 
In this step, patient-level treatment unblinding is done to enable a treatment comparison within 
each of the formed risk strata. Specifically, with 𝑌𝑌𝑞𝑞𝑘𝑘 denoting the log survival time for patient k 
within formed risk stratum q (1 ≤ 𝑞𝑞 ≤ 𝑐𝑐), we consider a basic log-linear form of the accelerated 
failure time model     
𝑌𝑌𝑞𝑞𝑘𝑘 = 𝜇𝜇𝑞𝑞 + 𝛿𝛿𝑞𝑞𝐼𝐼𝑞𝑞𝑘𝑘 + 𝜎𝜎𝑞𝑞𝜖𝜖𝑞𝑞𝑘𝑘                      (6) 
where 𝐼𝐼𝑞𝑞𝑘𝑘 is a treatment indicator (1 for treatment A and 0 for treatment B), 𝜖𝜖𝑞𝑞𝑘𝑘 is a random error 
term with an unknown density function, and 𝜇𝜇𝑞𝑞 and 𝜎𝜎𝑞𝑞 are intercept and scale parameters, 
respectively. The true comparative treatment effect for patients in formed risk stratum q is 𝛿𝛿𝑞𝑞. Note 
that each 𝛿𝛿𝑞𝑞 parameter is conditional on the overall population being represented as a mixture of 
subpopulations defined by the formed risk strata. While the formed risk strata will ultimately 
coincide with the true risk strata (conceptualized in the Introduction) with increasing sample size, 
this may not be the case for a given randomized clinical trial. Fortunately, this does not interfere 
with our main goal of estimation and inference for ∆ as long as we can obtain reliable estimates 
for each 𝛿𝛿𝑞𝑞; we return to this point when we discuss Step 5.      
 
While non-parametric analysis options for (6) do exist,39 our preference, motivated by support 
from real datasets, is to use parametric approaches. Liao and Liu40 have reported that treatment-
specific Kaplan-Meier curves formed from an overall (typically heterogenous) randomized clinical 
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trial patient population are often well approximated by parametric survival fits that assume survival 
times arise from a finite mixture of Weibull distributions. This mimics our own experience with 
the exploration of clinical trial datasets across different therapeutic areas. Given this, it is tempting 
to consider only a Weibull model fit for (6) in formed stratum q. However, we employ a model-
averaging idea to add a layer of robustness against misspecification of the assumed underlying 
survival time distribution. Specifically, we recommend estimating 𝛿𝛿𝑞𝑞 through a Weibull model 
(model 1), a log-normal model (model 2) and a log-logistic model (model 3), resulting in a point 
estimate ?̂?𝛿𝑞𝑞,𝑚𝑚 and corresponding variance 𝑉𝑉𝑞𝑞,𝑚𝑚 associated with model m=1,2,3. Here, the 
aforementioned Weibull, log-normal and log-logistic distributions refer to the distribution of 
survival times, with corresponding distributions for log survival times, or more specifically, for 
the random error terms in (6) being the extreme value (Gumbel), normal and logistic, respectively. 
While other parametric survival time distributions (e.g., gamma) can also be considered for (6), 
our experience suggests that the aforementioned three will generally suffice. Either way, it is 
important to stress that the parametric distributions to be used in the model-averaging need to be 
pre-specified in the analysis plan. 
 
The final point estimate of 𝛿𝛿𝑞𝑞 and corresponding variance are obtained using the following well-
known41 model-averaging formulas based on M model fits: 
𝑤𝑤𝑞𝑞,𝑚𝑚 = 𝑠𝑠−0.5𝐴𝐴𝐴𝐴𝐴𝐴𝑞𝑞,𝑚𝑚∑ 𝑠𝑠−0.5𝐴𝐴𝐴𝐴𝐴𝐴𝑞𝑞,𝑚𝑚𝑀𝑀𝑚𝑚=1            (7) 
 ?̂?𝛿𝑞𝑞 = ∑ 𝑤𝑤𝑞𝑞,𝑚𝑚?̂?𝛿𝑞𝑞,𝑚𝑚𝑀𝑀𝑚𝑚=1                    (8) 
𝑉𝑉𝑞𝑞 = �∑ 𝑤𝑤𝑞𝑞,𝑚𝑚�𝑉𝑉𝑞𝑞,𝑚𝑚 + �?̂?𝛿𝑞𝑞,𝑚𝑚 − ?̂?𝛿𝑞𝑞�2𝑀𝑀𝑚𝑚=1 �2.           (9) 
Above, 𝐴𝐴𝐼𝐼𝐴𝐴𝑞𝑞,𝑚𝑚 is a measure of the goodness-of-fit for parametric model m, quantified using the 
population Akaike Information Criterion, and 𝑤𝑤𝑞𝑞,𝑚𝑚 is the associated weight assigned to the fit from 
model m, all within formed risk stratum q. Based on large-sample theory, 
�𝛿𝛿�𝑞𝑞−𝛿𝛿𝑞𝑞�
�𝑉𝑉𝑞𝑞
 ~ N(0,1)               (10) 
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so that an approximate 100 × (1 − 𝛼𝛼)% confidence interval for 𝛿𝛿𝑞𝑞 is ?̂?𝛿𝑞𝑞 ∓ 𝑍𝑍𝛼𝛼/2�𝑉𝑉𝑞𝑞. The point 
estimate and confidence interval for the corresponding time ratio (i.e., 𝛾𝛾𝑞𝑞 = 𝑒𝑒𝛿𝛿𝑞𝑞) are easily 
obtained using exponentiation. In addition to the confidence interval for 𝛾𝛾𝑞𝑞, we recommend 
reporting an estimate of the probability that treatment A prolongs expected survival relative to 
treatment B in formed risk stratum q, i.e., 𝑃𝑃𝑃𝑃�𝛿𝛿𝑞𝑞 > 0� = 𝑃𝑃𝑃𝑃�𝛾𝛾𝑞𝑞 > 1�, calculated using (10). 
 
A natural alternative to the model in (6) is the popular Cox proportional hazards model. We prefer 
the former because there is no guarantee that the PH assumption will hold in each formed risk 
stratum, nor asymptotically in each of the true risk strata. There is, however, one exception which 
applies if the survival times for treatment B in formed risk stratum q follow a Weibull distribution 
and treatment A shifts the location of the log survival times under treatment B by 𝛿𝛿𝑞𝑞, as in (6). In 
this special case, it can be shown that the following identities will hold: 𝑙𝑙𝑙𝑙𝑙𝑙�ℎ𝑞𝑞𝐴𝐴(𝑡𝑡)� =
𝑙𝑙𝑙𝑙𝑙𝑙�ℎ𝑞𝑞𝐵𝐵(𝑡𝑡)� + 𝛽𝛽𝑞𝑞 and 𝑆𝑆𝑞𝑞𝐴𝐴(𝑡𝑡) = �𝑆𝑆𝑞𝑞𝐵𝐵(𝑡𝑡)�𝜃𝜃𝑞𝑞, where 𝛽𝛽𝑞𝑞 = −𝛿𝛿𝑞𝑞/𝜎𝜎𝑞𝑞 and 𝜃𝜃𝑞𝑞 = 𝑒𝑒𝛽𝛽𝑞𝑞 is the familiar 
hazard ratio.  Given our observation that a Weibull assumption for survival times within a 
prognostically homogeneous subpopulation will often (but not always) be reasonable, as a 
supplemental analysis, we recommend reporting a point estimate and confidence interval for each 
𝜃𝜃𝑞𝑞 and an estimate of 𝑃𝑃𝑃𝑃�𝜃𝜃𝑞𝑞 < 1�, all calculated using basic semi-parametric Cox PH model fits 
within each formed risk stratum. It should be recognized that these supplemental results will be 
hard to interpret if the PH assumption is clearly not supported by the data in one or more of the 
formed risk strata.    
 
Step 5: Amalgamation of results across formed risk strata for overall hypothesis testing and 
estimation 
After comparative treatment effect results within each formed risk stratum have been obtained, we 
are now ready to test 𝐻𝐻0∗ in (2) and to estimate ∆ (and subsequently 𝛾𝛾). Let 𝑛𝑛𝑞𝑞 and N denote the 
number of patients in formed risk stratum q and the total number of randomized patients in the 
trial, respectively. The test statistics 
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     𝑍𝑍𝐼𝐼 = ∑ 𝑚𝑚𝑞𝑞𝛿𝛿�𝑞𝑞𝑐𝑐𝑞𝑞=1
�∑ 𝑚𝑚𝑞𝑞
2𝑉𝑉𝑞𝑞
𝑐𝑐
𝑞𝑞=1
                (11) 
and       
     𝑍𝑍𝐼𝐼𝐼𝐼 = ∑ 𝑚𝑚𝑞𝑞𝑍𝑍𝑞𝑞𝑐𝑐𝑞𝑞=1
�∑ 𝑚𝑚𝑞𝑞
2𝑐𝑐
𝑞𝑞=1
          (12) 
are natural choices for testing 𝐻𝐻0∗, where 𝑍𝑍𝑞𝑞 =  ?̂?𝛿𝑞𝑞/�𝑉𝑉𝑞𝑞. Asymptotically, both 𝑍𝑍𝐼𝐼 and 𝑍𝑍𝐼𝐼𝐼𝐼 are 
distributed as N(0,1) under 𝐻𝐻0∗. Intuitively, for a one-tailed test in the direction favoring the test 
treatment, (11) will generally be more powerful than (12) if larger ?̂?𝛿𝑞𝑞 are expected a priori to be 
associated with larger 𝑉𝑉𝑞𝑞, such as when lower risk patients, who may have fewer events and at an 
overall slower rate, experience greater relative benefit from the test treatment. Since this type of 
information is typically unavailable at the design stage of the trial, instead of adopting either 𝑍𝑍𝐼𝐼 or 
𝑍𝑍𝐼𝐼𝐼𝐼 as a default, we recommend using  
 𝑍𝑍𝑚𝑚𝑚𝑚𝑚𝑚 = 𝑚𝑚𝑚𝑚𝑚𝑚(𝑍𝑍𝐼𝐼 ,𝑍𝑍𝐼𝐼𝐼𝐼)          (13) 
as the test statistic. The exact42 probability density function (PDF) of 𝑍𝑍𝑚𝑚𝑚𝑚𝑚𝑚 is    
    𝑓𝑓(𝑧𝑧𝑚𝑚𝑚𝑚𝑚𝑚) = 2𝜙𝜙(𝑧𝑧𝑚𝑚𝑚𝑚𝑚𝑚)Φ� 1−𝜌𝜌�1−𝜌𝜌2 𝑧𝑧𝑚𝑚𝑚𝑚𝑚𝑚�,        (14) 
where 𝜌𝜌 is the true correlation between 𝑍𝑍𝐼𝐼 and 𝑍𝑍𝐼𝐼𝐼𝐼; 𝜙𝜙(. ) and Φ(. ) are the density function and 
cumulative distribution function of the standard normal distribution, respectively. In practice, 𝜌𝜌 is 
typically very close to one and can be estimated remarkably well with    
  
     𝜌𝜌� = ∑ 𝑚𝑚𝑞𝑞2�𝑉𝑉𝑞𝑞𝑐𝑐𝑞𝑞=1
�∑ 𝑚𝑚𝑞𝑞
2𝑉𝑉𝑞𝑞
𝑐𝑐
𝑞𝑞=1 �∑ 𝑚𝑚𝑞𝑞
2𝑐𝑐
𝑞𝑞=1
.         (15) 
An asymptotic one-tailed p-value (p) for testing 𝐻𝐻0∗ in (2) is easily calculated using (11) to (15) 
and the null hypothesis is rejected if p < α/2 (= 0.025 by default). In large samples, rejection of 𝐻𝐻0∗ 
can be interpreted as reliable statistical evidence of treatment A prolonging survival relative to 
treatment B, on average, for patients in at least one of the formed risk strata, and hence by extension 
in at least one of the true risk strata. The justification for the latter extension is based on the 
following two lines of reasoning. First, because the formed strata and true strata represent almost 
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the same (if not identical) risk-based groupings of patients asymptotically. Second, a stratified 
analysis based on formed risk strata and a corresponding analysis based on (hypothetically known) 
true risk strata implicitly address the same estimand, ∆, which is zero under 𝐻𝐻0∗. This follows 
because, in a typical linear model analysis context, adjustment for a different set of baseline 
covariates changes the estimate but not the estimand.43  
 
The 5-STAR point estimate of ∆ is obtained as 
     ∆�= ∑ 𝑤𝑤𝑞𝑞𝛿𝛿�𝑞𝑞 𝑐𝑐𝑞𝑞=1
∑ 𝑤𝑤𝑞𝑞
𝑐𝑐
𝑞𝑞=1
                     (16)  
with asymptotic variance 
           𝑉𝑉�∆�� = ∑ 𝑤𝑤𝑞𝑞2V𝑞𝑞𝑐𝑐𝑞𝑞=1
�∑ 𝑤𝑤𝑞𝑞
𝑐𝑐
𝑞𝑞=1 �
2                     (17) 
where 𝑤𝑤𝑞𝑞 = 𝑛𝑛𝑞𝑞 if 𝑧𝑧𝑚𝑚𝑚𝑚𝑚𝑚 = 𝑧𝑧𝐼𝐼 and 𝑤𝑤𝑞𝑞 = 𝑛𝑛𝑞𝑞/�𝑉𝑉𝑞𝑞 if 𝑧𝑧𝑚𝑚𝑚𝑚𝑚𝑚 = 𝑧𝑧𝐼𝐼𝐼𝐼. An asymptotic 100 × (1 − 𝛼𝛼)% 
confidence interval for ∆ is calculated as ∆� ∓ 𝑍𝑍𝑚𝑚𝑚𝑚𝑚𝑚,𝛼𝛼/2�𝑉𝑉�∆�� where 𝑍𝑍𝑚𝑚𝑚𝑚𝑚𝑚,𝛼𝛼/2 is the relevant 
quantile based on the distribution in (14). Finally, point and confidence interval estimates for 𝛾𝛾 are 
obtained by exponentiating their counterparts for ∆ described above. Corresponding results for 
𝜃𝜃 = 𝑒𝑒𝛽𝛽, where 𝛽𝛽 = ∑ 𝑓𝑓𝑖𝑖𝛽𝛽𝑖𝑖𝑠𝑠𝑖𝑖=1 , can be easily obtained for a supplemental analysis, as needed, using 
basic Cox PH model fits with each of the formed risk strata and analogs of the formulas described 
above.         
 
3. THREE ILLUSTRATIVE EXAMPLES  
To help readers check their understanding of the 5-STAR method, and to illustrate its utility, we 
walk through its application in great detail using a hypothetical dataset, followed by application to 
two real datasets. The three examples differ primarily in terms of sample size, cardinality of the 
candidate set of baseline covariates in Step 1 of 5-STAR, and/or evidence of non-proportional 
hazards in the overall (i.e., unstratified) trial population. 
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Example 1 (hypothetical clinical trial) 
Consider a hypothetical clinical trial in which 600 patients were randomized with equal probability 
to either a test treatment (A) or a control treatment (B), without pre-stratification on any factor. 
Assuming proportional hazards, suppose that a clinically meaningful hazard ratio of 0.80 or less, 
loosely interpreted by some as ‘at least a 20% risk reduction’, was hoped for. Based on a simulated 
dataset, Figure 2 (left panel) shows Kaplan-Meier curves for each treatment along with a logrank 
test one-tailed p-value of 0.105 and estimated hazard ratio (95% CI) of 0.87 (0.70, 1.08) obtained 
from a basic Cox PH model. These results look both statistically and clinically disappointing. 
However, a crossing of the smoothed estimates of the log hazard functions and a p-value of 0.015 
from the popular Grambsch and Therneau [GT] test44 (right panel) provide cautionary evidence of 
non-proportional hazards. Unfortunately, even if non-PH was anticipated a priori in this 
hypothetical setting and one of the two alternatives to the logrank test discussed in the Introduction 
had been pre-specified in the analysis plan, the result would still have been disappointing: one-
tailed p-values of 0.057 and 0.182 for the MaxCombo and RMST test, respectively. In essence, 
application of the common approaches in current practice would have resulted in a ‘negative’ trial 
due to lack of statistical evidence of an overall survival benefit of the test versus the control 
treatment. We now show how the application of 5-STAR here leads to a different and more 
appropriate conclusion. 
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Figure 2. Kaplan-Meier curves for each treatment (left) and corresponding smoothed versions of 
estimated log hazard functions (right) for Example 1. 
 
Suppose 50 baseline covariates, generically labeled X1-X50, were pre-specified in Step 1 and 
included in the hypothetical dataset. Of these, based on elastic net Cox regression applied to the 
pooled survival times, i.e., blinded to patient-level treatment assignment, 6 binary covariates (X1, 
X2, X6, X7, X8, X15) and 4 continuous covariates (X26, X31, X38, and X40) are deemed potentially 
prognostic for survival in Step 2. For completeness, salient details of the optimization of the elastic 
net mixing and tuning parameters, (𝜓𝜓, 𝜆𝜆), and resulting ‘solution path’ are shown graphically in 
the left and right panels of Figure 3, respectively. 
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Figure 3. Graphical details for the elastic net Cox regression filtering step (Example 1). Left: each curve 
represents a mixing parameter 𝜓𝜓 and each dot represents the tuning parameter value 𝜆𝜆 with the smallest 
deviance. Here (𝜓𝜓, 𝜆𝜆) = (0.95, 0.04) is chosen to minimize deviance. Right: solution path for the chosen 
𝛼𝛼 value, showing how the coefficients for the elastic net model fit change over the range of 𝜆𝜆. Of the 50 
input covariates, ten (X1, X2, X6, X7, X8, X15, X26, X31, X38 and X40) have a non-zero coefficient at the 
optimal 𝜆𝜆 value (shown via dotted vertical line) 
 
 
Based on the CTree algorithm results, Figure 4 reveals the formation of six preliminary (top 
panel; Step 3A) and four final (bottom panel; Step 3B) risk strata defined by three baseline 
covariates: X1 (binary), X2 (binary) and X26 (continuous, with a 0.35 cut-point). The overall 
Kaplan-Meier curves pooled across treatment arms for the four final risk strata are clearly well-
separated, with median survival times steadily increasing when transitioning in order from the 
highest risk stratum (S1) to the lowest risk stratum (S4). 
 
Having reached Step 4 in the 5-STAR method, patient-level treatment unblinding can now be done. 
The resulting Kaplan-Meier curves for both treatments are shown within each formed risk stratum 
in the top panel of Figure 5. The bottom panel displays point estimates and 95% CIs for stratum-
level time ratios, along with corresponding estimates of the probability that the time ratio is greater 
than one. All these quantities were calculated using expressions (6) through (10). 
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Figure 4. Risk strata formation for Example 1 using the conditional inference tree algorithm blinded to patient-level treatment assignment. Left: 
results from Step 3A (preliminary risk strata) and Step 3B (final risk strata). Right: corresponding Kaplan-Meier curves for each risk stratum.
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Figure 5. Results from 5-STAR Step 4 and Step 5 for Example 1. Top: Kaplan-Meier curves by treatment within each formed risk stratum. Bottom: 
forest plot showing stratum-level results for each formed risk stratum as well as the overall (i.e., stratum-averaged) result. TR = time ratio, with 
TR > 1 favoring the test treatment. HR = hazard ratio, with HR < 1 favoring the test treatment. 
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Finally, in Step 5 of 5-STAR, the individual formed risk stratum results are combined using 
expressions (11) through (17) leading to the estimated average time ratio (95% CI) of 1.14 (1.05, 
1.24) shown in the bottom panel of Figure 5. Based on 𝑍𝑍𝐼𝐼 = 3.05, 𝑍𝑍𝐼𝐼𝐼𝐼 = 2.95 and 𝜌𝜌� = 0.992, the 
one-tailed p-value for 5-STAR is 0.001, providing strong statistical evidence that the test treatment 
prolongs survival relative to the control treatment, on average. This conclusion is different from 
that reached by the logrank, MaxCombo and RMST comparison tests. 
 
Importantly, while 5-STAR has detected an efficacy signal favoring the test treatment over the 
control treatment in an ‘overall’ sense, it does not automatically imply that the test treatment should 
be deemed a better efficacy option for all types of patients. We feel it is necessary to look for 
subgroup(s) of patients defined by the formed risk strata that may have a ‘concerningly’ small 
likelihood of longer survival for the test treatment versus the control treatment; among several 
subjective options, we recommend using 𝑃𝑃𝑃𝑃(𝑇𝑇𝑇𝑇 > 1) less than 20% as a flagging mechanism. 
Based on the results shown in Figure 5, since none of the formed risk strata get flagged, it seems 
reasonable to conclude that the test treatment is a generally better option than the control treatment 
for longer survival, on average, for patients across all risk strata in the target population. 
 
As a supplemental analysis, within each formed risk stratum, a point estimate and confidence 
interval for the hazard ratio along with a corresponding estimate of 𝑃𝑃𝑃𝑃(𝐻𝐻𝑇𝑇 < 1) are shown in the 
bottom panel of Figure 5. Also reported is the estimated average HR (95% CI) of 0.72 (0.57, 0.92); 
note that the upper bound of this CI is less than one and the point estimate is better than the 
aforementioned clinically meaningful threshold of 0.80. Importantly, these additional results are 
interpretable because no obvious departure from PH is detected within any formed risk stratum 
(GT p-values: 0.127, 0.987, 0.537, 0.507). Furthermore, it is reassuring to see that conclusions 
based on time ratios and hazard ratios are reasonably well aligned. 
 
Example 2 (real clinical trial; oncology therapeutic area) 
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We now consider a real Phase III randomized clinical trial described in Lipkovich et al.45 A total 
of 599 patients with a hematological malignancy were enrolled, with 303 receiving the 
experimental treatment and the remaining 296 receiving the control treatment. As no stratification 
factors were pre-specified for randomization or analysis, the [unstratified] logrank test was used 
for the primary analysis. This analysis missed the one-sided significance threshold of 0.025 with 
an overall one-tailed p-value of 0.035. The corresponding hazard ratio (95% CI), as estimated via 
an unstratified Cox PH model, was 0.85 (0.71, 1.01). Upon examining the Kaplan-Meier curves 
and estimated smoothed log hazards for each treatment (left and middle panels of Figure 6, 
respectively), we see hints of non-proportional hazards, with a separation in the curves occurring 
around the middle of the time points and crossing log hazard functions. The GT test yields a p-
value of 0.002, providing statistical evidence against proportional hazards. Unlike the hypothetical 
example, here the MaxCombo and RMST approaches do generate a retrospective statistical ‘win’ 
for the trial with one-tailed p-values of 0.004 and 0.014, respectively. However, they are not 
designed to deliver a reliable and interpretable estimate of the comparative treatment effect size, 
either overall or in relevant subgroups of patients.  
 
We now illustrate the application of 5-STAR to these data. In the study, 14 baseline covariates 
were recorded, including both nominal covariates (patient sex, race, prior therapy outcome and 
presence/absence of nine cytogenetic markers) and ordinal covariates (cytogenetic category and 
IPSS-R prognostic risk score). All these are included in Step 1. In Step 2, seven cytogenetic 
markers get filtered out using the elastic net Cox regression model; the remaining seven covariates 
are passed into the CTree algorithm, showing evidence of a possible prognostic association with 
survival. In Step 3A, five preliminary strata are formed. No pooling is done in Step 3B, leaving 
the same five final risk strata. The formed risk strata are defined using the following covariates: 
cytogenetic marker 6 (Cytogen6, Present (1) vs. Absent (0)), outcome of prior therapy (Priorout, 
with split between higher risk category “Progress” and lower risk categories {“Failure”, 
“Relapse”}), IPSS-R prognostic score (IPSS, with split between higher risk score groups {High 
(3), Very High (4)} and lower risk score groups {Low (1), Intermediate (2)}), and cytogenetic 
category (Cytogencat, with split between lower risk group {Very Good (1), Good (2) , Intermediate 
(3)} and higher risk group {Poor (4), Very Poor (5)}). The Kaplan-Meier curves for the five final 
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risk strata are shown in Figure 6 (right panel). While visually there may appear to be some overlap 
within two pairs of curves (medium risk strata S2-S3 and low risk strata S4-S5), there is a clear 
separation between the three groups of curves, a corresponding clear increase in median survival, 
and strong separation at early time points between the aforementioned curve pairs.  
 
After the final risk strata are formed, the within-stratum treatment effects are estimated in Step 4. 
The treatment-specific Kaplan-Meier curves for each formed stratum (top panel) and 
corresponding forest plot of estimated stratum-level time ratios and 95% confidence intervals 
(bottom panel) are provided in Figure 7. At the end of Step 5, the estimated average time ratio 
(95% CI) is 1.23 (1.08, 1.40). Furthermore, based on 𝑍𝑍𝐼𝐼 = 3.15, 𝑍𝑍𝐼𝐼𝐼𝐼 = 2.74 and 𝜌𝜌� = 0.990, the 
corresponding one-tailed p-value is 0.001. This shows strong evidence that the test treatment is 
beneficial in extending survival time, on average, i.e., for at least a subgroup of patients, relative 
to the control treatment. As in the previous example, we now take a closer look at the formed risk 
stratum-level results. Here, for the higher risk patients (S1-S3, corresponding to about 50% of the 
patients) the test treatment is estimated to prolong expected survival by an impressive 50-85% 
over the control treatment, with greater than 99% probability that the true time ratio exceeds 1. In 
contrast, there is no evidence that the test treatment will be more beneficial for the lowest risk 
patients (S5) where 𝑃𝑃𝑃𝑃(𝑇𝑇𝑇𝑇 > 1) is < 5%. In a regulatory setting, it would seem reasonable to 
question the approvability of the test treatment for this 12% subset of the target patient population, 
corresponding to patients with lower IPSS risk scores and better cytogenetic categories.  
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Figure 6. Kaplan-Meier curves for each treatment (left) and corresponding smoothed versions of estimated log hazard functions (middle) for 
Example 2. Right: KM curves for final risk strata formed using the conditional inference tree algorithm blinded to patient-level treatment 
assignment.
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Figure 7. Results from 5-STAR Step 4 and Step 5 for Example 2. Top: Kaplan-Meier curves by treatment within each formed risk stratum. Bottom: 
forest plot showing stratum-level results for each formed risk stratum as well as the overall (i.e., stratum-averaged) result. TR = time ratio, with 
TR > 1 favoring the test treatment. HR = hazard ratio, with HR < 1 favoring the test treatment. 
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For the most part, conclusions are consistent when examining the supplemental hazard ratio 
results. The overall estimated average HR (95% CI) is 0.81 (0.66, 0.99), which is more promising 
both statistically and clinically compared to the corresponding result from the prespecified analysis 
(Cox PH model). Of note is the second highest formed risk stratum S2, where the estimated hazard 
ratio (95% CI) is 0.94 (0.69, 1.30) with less than 62% probability that the true hazard ratio is less 
than one. This shows materially lower evidence of test treatment versus control treatment benefit 
as compared to that based on the time ratio-based estimate. However, this stratum, along with 
strata S1 and S3 show evidence of non-PH (GT p-value < 0.02 in all three strata, and < 0.0001 in 
S2); this makes the hazard ratio results hard to interpret, amplifying the utility of the corresponding 
primary analysis results using time ratios. 
 
Example 3 (real clinical trial; cardiovascular therapeutic area) 
As a final example, we consider a large phase III cardiovascular clinical trial.46 This randomized 
study enrolled 18,144 patients who had recently experienced an acute coronary syndrome: 9,067 
received the test treatment and 9,077 received the control treatment (standard of care). 
Randomization was stratified based on three pre-defined baseline factors: PLL (prior use of lipid 
lowering therapy, a binary variable indicating whether or not a patient had used statins before trial 
initiation), ACSD (type of acute coronary syndrome experienced, STEMI (ST-Elevation 
Myocardial Infarction) or non-STEMI), and EACS (representing patient participation status in a 
previous cardiovascular trial: unenrolled, enrolled receiving test treatment, or enrolled receiving 
control treatment). As only non-STEMI patients were enrolled in the EACS trial, eight pre-defined 
strata were used for randomization and subsequent protocol-defined analyses.  
 
For illustrative purposes, we focus on the time to stroke (fatal or non-fatal), a clinically important 
exploratory endpoint for the trial with over 95% censoring. The Kaplan-Meier curves for each 
treatment arm are shown in the left panel of Figure 8; unlike the previous two examples, here there 
is no evidence of non-proportional hazards, with a GT p-value of 0.479. In the middle panel, we 
provide the overall (i.e., pooled across treatment arms) Kaplan-Meier curves for each of the eight 
pre-defined strata. There is a substantial amount of overlap in some of the curves, indicating a 
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potentially suboptimal choice of pre-stratification factor(s) leading to over-stratification. The pre-
specified stratified logrank test just falls short of statistical significance at the one-sided 0.025 
alpha level, with a p-value of 0.026 and corresponding HR (95% CI) of 0.86 (0.73, 1.00) as 
estimated via the stratified Cox PH model. The corresponding one-tailed p-values for the RMST 
comparison and MaxCombo test are 0.024 and 0.039, respectively. 
 
We now apply the 5-STAR method to this large dataset. Forty-five potentially prognostic variables 
are specified in Step 1, including demographic, clinical disease history, and baseline lipid level 
information. Of these, blinded to patient-level treatment assignment, 22 pass the filtering step in 
Step 2 as having some evidence of association with survival time. Finally, in Step 3, five 
preliminary and four final risk strata are formed based on continuous variable age (with cut-point 
at 67 years) and three binary patient history variables: HSCD (history of cerebrovascular disease), 
HSAF (history of atrial fibrillation), and PRMI (prior myocardial infarction). Overall Kaplan-
Meier curves for the four final formed risk strata are shown in the right panel of Figure 8. There is 
a much more distinct separation in the pooled survival curves compared to that in the plot with the 
curves based on the pre-specified strata (middle panel). In particular, the highest formed risk 
stratum has clearly worse prognosis compared to the other three, which still have close to no 
overlap. This example vividly illustrates how the objective risk-based patient segmentation 
component of 5-STAR can reveal ‘structured’ patient heterogeneity using an algorithm that is 
blinded to patient-level treatment assignment. This type of information, important both from a 
clinical and statistical perspective, often remains hidden when viewed through strata defined by 
(often subjectively chosen) pre-stratification factors at the design stage of the trial.  
 
Kaplan-Meier curves for both treatments within each formed risk stratum (top panel) and a 
corresponding forest plot of the estimated comparative treatment effects (bottom panel) are shown 
in Figure 9, illustrating the components behind the overall comparative treatment effect estimate 
obtained in Step 5 of 5-STAR. The average estimated time ratio (95% CI) is 1.30 (1.04, 1.81), 
indicating that, on average, patients on the test treatment have 30% longer stroke-free time 
compared to those on the control treatment. Based on 𝑍𝑍𝐼𝐼 = 2.32, 𝑍𝑍𝐼𝐼𝐼𝐼 = 2.36 and 𝜌𝜌� = 0.998, the 
corresponding one-tailed p-value is 0.010, indicating statistical evidence of efficacy benefit from 
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the test treatment compared to the control for at least some patients. Looking at the results within 
the formed risk strata, the lowest risk patients (i.e., those that are less than 67 years of age, with 
no prior MI and no history of cerebrovascular disease [S4]), representing just over half of all 
patients, have the largest apparent gain from taking the test treatment with an estimated time ratio 
(95% CI) of 1.50 (1.04, 1.61) and 99% probability of improved survival benefit (Pr(𝑇𝑇𝑇𝑇 > 1)) 
relative to the control treatment. The supplemental hazard ratio-based results are clinically 
consistent with the time ratio results, with average hazard ratio (95% CI) of 0.81 (0.67, 0.97), and 
an estimated hazard ratio (95% CI) in formed risk stratum S4 of 0.70 (0.55, 0.90) with over 99% 
probability that the true hazard ratio is less than one for such patients. Of note, none of the Pr(𝑇𝑇𝑇𝑇 > 1) or Pr(𝐻𝐻𝑇𝑇 < 1) values shown in Figure 9 are even close to being lower than 20%, our 
subjective threshold of concern introduced in Example 1. Accordingly, if these results were to 
serve as the primary basis for a regulatory action, we believe it would be reasonable to consider 
approvability of the test treatment for patients across all risk strata. 
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Figure 8. Kaplan-Meier (KM) curves for Example 2. Left: KM curves for test and control treatments. Middle: KM curves for each pre-specified 
stratum defined in the study protocol. Right: KM curves for final risk strata formed using the conditional inference tree algorithm blinded to 
patient-level treatment assignment.
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Figure 9. Results from 5-STAR Step 4 and Step 5 for Example 3. Top: Kaplan-Meier curves by treatment within each formed risk stratum. Bottom: 
forest plot showing stratum-level results for each formed risk stratum as well as the overall (i.e., stratum-averaged) result. TR = time ratio, with 
TR > 1 favoring the test treatment. HR = hazard ratio, with HR < 1 favoring the test treatment. 
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4. SIMULATION STUDY 
4.1 Set-up 
We simulated a clinical trial setting in which 600 patients are randomized in a 1:1 ratio to receive 
either a test treatment (A) or control treatment (B). For each patient, 50 correlated baseline 
covariates, 𝑋𝑋1-𝑋𝑋25 binary and 𝑋𝑋26-𝑋𝑋50 continuous, are measured. The heterogeneous patient 
population consists of four distinct prognostic subpopulations (risk strata) defined by a joint 
composite of two binary covariates (𝑋𝑋1 and 𝑋𝑋2) and one dichotomized continuous covariate (𝑋𝑋26 ≤0.4), as shown in Table 1. We set the true marginal means of the binary and continuous covariates 
to be 0.5 and 0, respectively. Furthermore, we assumed a true pairwise correlation of 0.2 between 
the three aforementioned prognostic covariates and sampled from 𝑁𝑁(0, 𝑠𝑠𝑑𝑑 = 0.15) for all other 
pairwise correlations; these correlations were motivated by real datasets across different 
therapeutic areas (details omitted).  
 
Table 1 
Simulation conditions showing four true risk strata defined by three baseline covariates, and 
median survival time for the control treatment, hazard ratio (HR) and time ratio (HR) within each 
true risk stratum 
Risk 
Stratum X1 X2 X26 
Median 
Survival  
(control 
treatment) 
Simulation Scenarios and Stratum-level 
Treatment Effects 
Null 
HR = 1 
Alt-1 
Equal HRs 
Alt-2 
Increasing HRs 
Alt-3 
Decreasing HRs 
HR TR HR TR HR TR HR TR 
S1 0 0 ≤ 0.4 6.0 months 1 1 0.7 1.15 0.42 1.42 0.95 1.02 0 1 ≤ 0.4 
S2 0 0 > 0.4 8.4 months 1 1 0.7 1.13 0.7 1.13 0.86 1.05 1 0 ≤ 0.4 
S3 0 1 > 0.4 10.8 months 1 1 0.7 1.11 0.86 1.04 0.7 1.11 1 1 ≤ 0.4 
S4 1 0 > 0.4 13.2 months 1 1 0.7 1.09 0.95 1.01 0.42 1.24 1 1 > 0.4 
 
For each treatment group, the random number of patients enrolled from each of the four risk strata 
was sampled from a 𝑚𝑚𝑢𝑢𝑙𝑙𝑡𝑡𝑖𝑖𝑛𝑛𝑙𝑙𝑚𝑚𝑖𝑖𝑚𝑚𝑙𝑙(𝑛𝑛 = 300,𝑝𝑝1 = 𝑝𝑝2 = 𝑝𝑝3 = 𝑝𝑝4 = 0.25) distribution. (Of note, 
simulations with unequal prevalence across the risk strata were also conducted and yielded similar 
conclusions; details omitted). A trial entry time for each patient 𝑘𝑘 = 1, … ,𝑛𝑛𝑖𝑖 within risk stratum 
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𝑖𝑖 = 1, … ,4, ordered from highest risk to lowest risk, and treatment 𝑗𝑗 = 𝐴𝐴,𝐵𝐵 was generated as 
𝑒𝑒𝑖𝑖𝑗𝑗𝑘𝑘~𝑈𝑈𝑛𝑛𝑖𝑖𝑓𝑓𝑙𝑙𝑃𝑃𝑚𝑚(0,𝐸𝐸) where 𝐸𝐸 = 0.75 years, or 9 months. True survival times were generated 
from a Weibull distribution with shape and scale parameters determined by risk stratum 
membership and treatment assignment as 𝑆𝑆𝑖𝑖𝑗𝑗𝑘𝑘 ∼ Weibull�𝑠𝑠ℎ𝑚𝑚𝑝𝑝𝑒𝑒 = 𝜅𝜅𝑖𝑖 , 𝑠𝑠𝑐𝑐𝑚𝑚𝑙𝑙𝑒𝑒 = 𝜂𝜂𝑖𝑖𝑗𝑗�, where 𝜿𝜿 =(𝜅𝜅1, 𝜅𝜅2, 𝜅𝜅3, 𝜅𝜅4) = (2.5, 3, 3.5, 4), and 𝜂𝜂𝑖𝑖𝐵𝐵 back-calculated from the shape and desired median 
survival time for the control treatment arm (in years) of each stratum, 𝒎𝒎𝐵𝐵 =(𝑚𝑚1𝐵𝐵,𝑚𝑚2𝐵𝐵,𝑚𝑚3𝐵𝐵,𝑚𝑚4𝐵𝐵) = (0.5, 0.7, 0.9, 1.1), as 𝜂𝜂𝑖𝑖𝐵𝐵 = 𝑚𝑚𝑖𝑖𝐵𝐵 × ln(2)− 1𝜅𝜅𝑖𝑖. Scale parameters in the test 
treatment arm were calculated as 𝜂𝜂𝑖𝑖𝐴𝐴 = 𝜂𝜂𝑖𝑖𝐵𝐵 × 𝜃𝜃𝑖𝑖− 1𝜅𝜅𝑖𝑖 , where 𝜃𝜃𝑖𝑖 was the hazard ratio for stratum 𝑖𝑖. 
This set-up ensured proportional hazards in truth within each risk stratum. 
 
In each simulated trial, patients were followed until 330 deaths had accrued. This target event total 
is often chosen in practice because it gives approximately 90% power for the logrank test when 
the proportional hazards assumption holds, the true hazard ratio is 0.7, and testing is done at the 
one-tailed alpha=0.025 level. The ‘observed’ simulated data for each trial were (𝑇𝑇𝑖𝑖𝑗𝑗𝑘𝑘,𝛿𝛿𝑖𝑖𝑗𝑗𝑘𝑘, 𝑚𝑚𝑖𝑖𝑗𝑗𝑘𝑘), 
where 𝑇𝑇𝑖𝑖𝑗𝑗𝑘𝑘 = min (𝑆𝑆𝑖𝑖𝑗𝑗𝑘𝑘,𝐴𝐴 − 𝑒𝑒𝑖𝑖𝑗𝑗𝑘𝑘) was the observed survival time, 𝐴𝐴 was the random time at which 
330 events had accrued, indicating end of patient follow-up, 𝛿𝛿𝑖𝑖𝑗𝑗𝑘𝑘 = 𝐼𝐼�𝑆𝑆𝑖𝑖𝑗𝑗𝑘𝑘 > 𝐴𝐴 − 𝑒𝑒𝑖𝑖𝑗𝑗𝑘𝑘� was the 
censoring indicator, equal to 0 for all patients whose true event time was observed and 1 for all 
patients who were censored, and 𝑚𝑚𝑖𝑖𝑗𝑗𝑘𝑘 was the vector of patient-level baseline covariate data.  
 
Four scenarios were considered to evaluate the performance of the competing methods under 
different patterns of hazard ratios across the risk strata. First, to evaluate type I error, a null scenario 
was considered in which there was no treatment difference in any of the risk strata, i.e., 𝜽𝜽 =(𝜃𝜃1, 𝜃𝜃2,𝜃𝜃3,𝜃𝜃4) = (1,1,1,1). Three alternative scenarios were also considered, all with an average 
log hazard ratio of 𝛽𝛽 = ∑ 𝑓𝑓𝑖𝑖𝛽𝛽𝑖𝑖𝑠𝑠𝑖𝑖=1 = 𝑙𝑙𝑛𝑛(0.7), with 𝜃𝜃𝑖𝑖 = 𝑒𝑒𝛽𝛽𝑖𝑖 , as noted in Section 2. In Alt-1 we set 
𝜽𝜽 = (0.7, 0.7, 0.7, 0.7), i.e., equal hazard ratios across the ordered risk strata. In Alt-2 we set 𝜽𝜽 =(0.42, 0.7, 0.86, 0.95), i.e., increasing hazard ratios, implying larger survival benefit of the test 
versus the control treatment for patient subpopulations with higher risk. Finally, in Alt-3 we set 
𝜽𝜽 = (0.95, 0.86, 0.7, 0.42), i.e., decreasing hazard ratios, implying larger survival benefit of the 
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test versus the control treatment for patient subpopulations with lower risk. All the scenarios are 
summarized in Table 1. In addition to the true hazard ratios for each risk stratum, we have also 
shown the corresponding true time ratios calculated as 𝛾𝛾𝑖𝑖 = 𝑒𝑒∆𝑖𝑖, where ∆𝑖𝑖= −𝛽𝛽𝑖𝑖/𝜅𝜅𝑖𝑖. 
 
We compared the performance of 5-STAR (both time ratio and hazard ratio versions) with that of 
the unstratified logrank test/Cox PH model, a misspecified stratified logrank test/Cox PH model, 
the MaxCombo and the RMST comparison methods. The misspecified stratified logrank test/Cox 
PH model was intended to mimic a realistic setting in which expert knowledge may guide 
researchers to correctly identify only a subset of the true prognostic covariates at the trial planning 
stage; in effect, either some prognostic covariates are missed, suboptimal cut-offs are selected for 
dichotomization of prognostic continuous covariates, or non-prognostic covariates are erroneously 
used for pre-stratification. Here, our pre-specified stratified Cox model analysis reflected strata 
defined by ‘correct’ covariates 𝑋𝑋2 and 𝑋𝑋26 (the latter discretized using a slightly suboptimal cut-
off of zero instead of the truly optimal 0.4) as well as an incorrect, i.e., non-prognostic, covariate 
𝑋𝑋3.  
 
In each of the four simulation scenarios, for each competing method, we computed the proportion 
of times in 20,000 simulated trials that the null hypothesis 𝐻𝐻0∗ in (2), equivalent in this setting to 
𝐻𝐻0
∗∗ in (4) and to 𝐻𝐻0 in (1), was rejected at the one-sided 2.5% significance level incorrectly (for 
type I error) or correctly (for power). For 5-STAR, we also calculated mean percent bias for the 
average time ratio (𝛾𝛾) and average hazard ratio (𝜃𝜃) estimands along with the corresponding 
coverage of the 95% CI for each parameter; these metrics were also calculated for the unstratified 
and stratified Cox PH model fits with 𝜃𝜃 serving as the target estimand. Finally, to help understand 
the key drivers of the main 5-STAR results, we examined the performance of the elastic net 
filtering step (Step 2) and the CTree step (Step 3) in terms of removal of noise covariates and use 
of correct (i.e., truly prognostic) covariates to define the risk strata, respectively. 
 
4.2 Results 
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Type I error and power 
As shown in Table 2, the type I error rate was well-controlled, on the basis of being less than 0.025 + 2�(0.025 × 0.975)/20,000  = 2.72%, for all the competing methods. In terms of 
power, both the time ratio (TR) and hazard ratio (HR) versions of 5-STAR performed admirably. 
Under Alt-1, both 5-STAR [TR] and 5-STAR [HR] had 84% power, which was 7 to 17 percentage 
points higher than the power of the best (stratified logrank) and worst (MaxCombo) performers 
among the other methods. Under Alt-2, 5-STAR [TR] placed first with 93% power followed by a 
tie for second place between 5-STAR [HR] and stratified logrank (90% power each), well-
separated from the other methods which had powers ranging from 82% to 84%. Finally, under Alt-
3, the best two performers were 5-STAR [HR] with 73% power and 5-STAR [TR] with 67% 
power, both notably more powerful than the other methods which had powers ranging from 48% 
to 54%. 
Table 2 
Summary of simulation results: type I error (target α=2.5%), power, and mean percent bias and 
coverage of 95% CI for the relevant target estimand (average HR or TR) based on 20,000 
simulations under each scenario 
Scenario: 
True HRs in risk strata: 
Null 
1, 1, 1, 1 
Alt-1 
0.7, 0.7, 0.7, 0.7 
Alt-2 
0.42, 0.7, 0.86, 0.95 
Alt-3 
0.95, 0.86, 0.7, 0.42 
Analysis Method Type I Error (%) 
Power 
(%) 
Mean  
% Bias 
95% CI 
Coverage 
Power 
(%) 
Mean 
% Bias 
95% CI 
Coverage 
Power 
(%) 
Mean 
% Bias 
95% CI 
Coverage 
Unstratified logrank/CPH 2.56 71 9.1 88.3 82 4.9 93.3 50 15.9 74.9 
Stratified logrank/CPH* 2.49 77 6.1 92.3 90 -0.3 95.0 48 15.9 76.1 
MaxCombo 2.60 67 -- -- 83 -- -- 54 -- -- 
RMST 2.51 71 -- -- 84 -- -- 48 -- -- 
5-STAR [TR] 2.49 84 0.3 95.8 93 0.2 95.3 67 0.3 96.0 
5-STAR [HR] 2.52 84 0.4 95.9 90 -2.7 94.9 73 1.2 96.1 
 
CPH = Cox proportional hazards model, * analysis strata based on three pre-specified factors (two 
prognostic and one non-prognostic, in truth), TR = time ratio, HR = hazard ratio 
 
Percent bias and coverage of 95% CI for target estimand 
As shown in Table 2, point estimates using 5-STAR [TR] and 5-STAR [HR] were associated with 
negligible bias for their respective average time ratio (γ) and average hazard ratio (θ) target 
estimands. Moreover, the 5-STAR 95% confidence intervals captured their true target estimand 
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very close to 95% of the time in every scenario studied.  In contrast, the unstratified and stratified 
Cox PH analyses were associated with point estimates for θ that were notably biased under Alt-1 
and Alt-3, with corresponding 95% confidence intervals having considerable under-coverage of 
the target parameter.   
 
5-STAR: effectiveness of covariate filtering (Step 2) and risk strata formation (Step 3) 
The elastic net Cox regression algorithm using pooled survival times blinded to patient-level 
treatment assignment did a reasonably good job filtering out noise covariates in Step 2 of 5-STAR. 
Across the four simulated scenarios, on average, approximately 9-10 of the 50 candidate covariates 
advanced to Step 3, with all of the correct (i.e., truly prognostic) covariates 𝑋𝑋1, 𝑋𝑋2 and 𝑋𝑋26 
advancing approximately 94-99% of the time. The CTree algorithm used for stratum formation in 
Step 3 of 5-STAR also performed reasonably well. Across the four simulated scenarios, on 
average, 3.4 covariates defined the final formed risk strata, with the latter based on at least the 
three correct covariates 83-98% of the time and based on only the three correct covariates 48-64% 
of the time. 
 
5. Concluding remarks 
The power of the ubiquitous logrank test for a between-treatment comparison of survival times in 
randomized clinical trials can be notably less than desired if the treatment hazard functions are 
non-proportional, and the accompanying hazard ratio estimate from a Cox proportional hazards 
model can be hard to interpret. Increasingly popular approaches to guard against the statistical 
adverse effects of non-proportional hazards include the MaxCombo test (based on a versatile 
combination of weighted logrank statistics) and a test based on a between-treatment comparison 
of restricted mean survival time (RMST). Unfortunately, neither the logrank test nor the latter two 
approaches are designed to leverage what we refer to as structured patient heterogeneity in clinical 
trial populations, and this can contribute to suboptimal power for detecting a between-treatment 
difference in the distribution of survival times. Stratified versions of the logrank test and the 
corresponding Cox proportional hazards model based on pre-specified stratification factors 
represent steps in the right direction. However, they carry unnecessary risks associated with both 
 
 
35 
a potential suboptimal choice of stratification factors and with potentially implausible dual 
assumptions of proportional hazards within each stratum and a constant hazard ratio across strata.  
 
We have developed and described a novel alternative to the aforementioned current approaches 
for survival analysis in randomized clinical trials. Our approach envisions the overall patient 
population as being a finite mixture of subpopulations (risk strata), with higher to lower ordered 
risk strata comprised of patients having shorter to longer expected survival regardless of treatment 
assignment. Patients within a given risk stratum are deemed prognostically homogeneous in that 
they have in common certain pre-treatment characteristics that jointly strongly associate with 
survival time. Given this conceptualization and motivated by a reasonable expectation that 
detection of a true treatment difference should get easier as the patient population gets 
prognostically more homogeneous, our proposed method follows naturally. Starting with a pre-
specified set of baseline covariates (Step 1), elastic net Cox regression (Step 2) and a subsequent 
conditional inference tree algorithm (Step 3) are used to segment the trial patients into ordered risk 
strata; importantly, both steps are blinded to patient-level treatment assignment. After unblinding, 
a treatment comparison is done within each formed risk stratum (Step 4) and stratum-level results 
are combined for overall estimation and inference (Step 5).  
 
For the primary analysis, labeled 5-STAR [TR], exponentiated estimates of between-treatment 
differences in mean log survival time, referred to as time ratios, are used for treatment comparisons 
within the formed risk strata. Estimation is accomplished using three accelerated failure time 
model fits (assuming survival times follow either a Weibull, log-normal or log-logistic 
distribution) in conjunction with straightforward model averaging. As a supplemental analysis, 
labeled 5-STAR [HR], hazard ratio estimates from basic Cox proportional hazard model fits within 
formed risk strata can be used, with the usual understanding that a hazard ratio estimate is hard to 
interpret if the corresponding treatment hazard functions are non-proportional. In addition to each 
formed stratum-level point estimate and 95% confidence interval for a time ratio (and hazard ratio, 
if needed), we recommend reporting a corresponding estimate of the probability that the test 
treatment is associated with expected longer survival than the control treatment. This level of detail 
in stratum-level reporting, currently uncommon in practice, provides transparency that aids in 
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understanding the key inputs for the overall (i.e., stratum-averaged) result. Moreover, it serves as 
a potential enabler of personalized medicine by drawing attention to any identifiable subgroup of 
patients defined by the formed strata that may have a notably low likelihood of experiencing longer 
survival with the test treatment relative to the control treatment despite an overall statistically 
significant result in favor of the test treatment.  
 
In summary, using a detailed analysis of a hypothetical dataset, retrospective analyses of two real 
datasets, and results from a simulation study, we have illustrated the impressive power-boosting 
performance and utility of our proposed 5-step stratified testing and amalgamation routine (5-
STAR) relative to that of the logrank test and other common approaches that are not designed to 
leverage inherently structured patient heterogeneity. We end by making observations on two 
unrelated but important fronts. First, suppose an interim analysis is planned for a randomized 
clinical trial to enable a potentially earlier conclusion of either futility or overwhelming success 
for the test treatment. With application of 5-STAR in mind, it is natural to inquire whether the risk 
strata formed at the interim analysis should be re-used for the subsequent final analysis (if 
applicable), or whether the risk strata formation step should be repeated for the latter. Second, even 
though the focus of this manuscript has been on survival analysis, the 5-STAR concept can be 
extended to analyses of continuous, ordinal and nominal endpoints. Research on both fronts is 
ongoing and will be the subject of future communications.   
 
Software: the 5-STAR methodology proposed in this manuscript can be easily implemented using 
the fiveSTAR R package available at https://github.com/rmarceauwest/fiveSTAR. 
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